MannKind News

MannKind Price Target Maintained With a $6.50/Share by Cantor Fitzgerald

MannKind Price Target Maintained With a $6.50/Share by Cantor Fitzgerald

Dow JonesMay 9 23:06

Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $6.5 Price Target

Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind with a Overweight and maintains $6.5 price target.

Analyst UpgradesMay 9 22:56

MannKind Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 50.99% Cantor Fitzgerald → $6.5 Reiterates Overweight → Overweight 03/15/2024 50.99% Cantor Fit

BenzingaMay 9 22:54

Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (LENZ), MannKind (MNKD) and Aquestive Therapeutics (AQST)

TipRanksMay 9 18:50

Earnings Call Summary | MannKind(MNKD.US) Q1 2024 Earnings Conference

The following is a summary of the MannKind Corporation (MNKD) Q1 2024 Earnings Call Transcript:Financial Performance:MannKind Corporation reported Q1 revenue growth of over 250% in the last eight quar

Futu NewsMay 9 16:31 · Conference Call

MannKind Corporation (MNKD) Q1 2024 Earnings Call Transcript

MannKind Corporation (MNKD) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 9 08:55

Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics

Yahoo FinanceMay 9 07:30

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates

Yahoo FinanceMay 9 07:10

MannKind Corp. Q1 Earnings Summary

RTTNewsMay 9 04:51

MannKind Q1 2024 Adj EPS $0.05 Beats $0.03 Estimate, Sales $66.263M Beat $60.490M Estimate

MannKind (NASDAQ:MNKD) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. This is a 350 percent increase over losses of $(0.02) per sha

BenzingaMay 9 04:42

Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05

04:19 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05

MT NewswiresMay 9 04:19

Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, Vs. Street Est of $60.6M

04:19 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M

MT NewswiresMay 9 04:19

MannKind | 10-Q: Quarterly report

Futu NewsMay 9 04:18 · Announcements

MannKind 1Q EPS 4c >MNKD

MannKind 1Q EPS 4c >MNKD

Dow JonesMay 9 04:18

MannKind 1Q Net $10.6M >MNKD

MannKind 1Q Net $10.6M >MNKD

Dow JonesMay 9 04:18

MannKind 1Q Rev $66.3M >MNKD

MannKind 1Q Rev $66.3M >MNKD

Dow JonesMay 9 04:18

Press Release: MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update

MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update Conference Call to Begin Today at 5:00 p.m. (ET) -- 1Q 2024 Total revenues of $66M; +63% vs

Dow JonesMay 9 04:18

MannKind Q1 24 Earnings Conference Call At 5:00 PM ET

RTTNewsMay 9 03:00

MannKind Receives FDA Fast Track Designation for Its Potential Lung Disease Treatment

MannKind (MNKD) said Monday it received US Food and Drug Administration fast track designation for clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial lung disease. Fas

MT NewswiresMay 6 18:38

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled th

MannkindMay 6 12:00